Nuclear factor-κ13 in development, prevention, and therapy of cancer

被引:255
作者
Van Waes, Carter
机构
[1] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Bethesda, MD 20892 USA
[2] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-06-2221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear factor-kappa B (NF-kappa B) is a signal transcription factor that has emerged as an important modulator of altered gene programs and malignant phenotype in development of cancer. Major carcinogens and oncogenic viruses induce NF-kappa B activation, and a variety of subsequent oncogenic events contribute to a progressive increase in constitutive NF-kappa B activation as an important common pathway in most forms of cancer. NF-kappa B target genes promote tumor cell proliferation, survival, migration, inflammation, and angiogenesis. Inhibition of NF-kappa B has been found to be an important mechanism of action of steroids, nonsteroidal anti-inflammatory drugs, and natural and synthetic compounds that show therapeutic and preventive activity. Newer agents targeting the proteasome, inhibitor-kappa B kinase, and other upstream kinases involved in NF-kappa B activation have shown anticancer activity in clinical or preclinical studies.
引用
收藏
页码:1076 / 1082
页数:7
相关论文
共 100 条
[91]   The putative oncoprotein Bcl-3 induces cyclin d1 to stimulate G1 transition [J].
Westerheide, SD ;
Mayo, MW ;
Anest, V ;
Hanson, JL ;
Baldwin, AS .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (24) :8428-8436
[92]  
Wolf JS, 2001, CLIN CANCER RES, V7, P1812
[93]   Defective IκBα in Hodgkin cell lines with constitutively active NF-κB [J].
Wood, KM ;
Roff, M ;
Hay, RT .
ONCOGENE, 1998, 16 (16) :2131-2139
[94]   Sulindac inhibits activation of the NF-κB pathway [J].
Yamamoto, Y ;
Yin, MJ ;
Lin, KM ;
Gaynor, RB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (38) :27307-27314
[95]   Bortezomib (VELCADE®) in metastatic breast cancer:: pharmacodynamics, biological effects, and prediction of clinical benefits [J].
Yang, CH ;
Gonzalez-Angulo, AM ;
Reuben, JM ;
Booser, DJ ;
Pusztai, L ;
Krishnamurthy, S ;
Esseltine, D ;
Stec, J ;
Broglio, KR ;
Islam, R ;
Hortobagyi, GN ;
Cristofanilli, M .
ANNALS OF ONCOLOGY, 2006, 17 (05) :813-817
[96]   BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma:: Involvement of nuclear factor κB and mitochondria pathways [J].
Yang, JM ;
Amiri, KI ;
Burke, JR ;
Schmid, JA ;
Richmond, A .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :950-960
[97]   Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells [J].
Yemelyanov, A ;
Gasparian, A ;
Lindholm, P ;
Dang, L ;
Pierce, JW ;
Kisseljov, F ;
Karseladze, A ;
Budunova, I .
ONCOGENE, 2006, 25 (03) :387-398
[98]   The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β [J].
Yin, MJ ;
Yamamoto, Y ;
Gaynor, RB .
NATURE, 1998, 396 (6706) :77-80
[99]   Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells [J].
Yu, Mng ;
Yeh, Jason ;
Van Waes, Carter .
CANCER RESEARCH, 2006, 66 (13) :6722-6731
[100]   NF-κB RelA poses epidermal proliferation riven by TNFR1 and JNK [J].
Zhang, JY ;
Green, CL ;
Tao, SY ;
Khavari, PA .
GENES & DEVELOPMENT, 2004, 18 (01) :17-22